Age-related macular degeneration (AMD) is the most common cause of irreversible blindness for older people. A recently published case-control study examined people 55 years and older with newly diagnosed AMD , enrolling 312 404 people with AMD and matching them with 312 376 controls. Those with AMD had a slightly higher percentage of participants with diabetes (26.0%) compared with the control group (25.5%). The use of metformin was found to be associated with reduced odds of developing AMD (odds ratio [OR], 0.94 [95% CI, 0.92-0.96]), and moreover the association was dose dependent: low to moderate doses of metformin showing the greatest potential benefit (dosages over 2 years: 1-270 g, OR, 0.91 [95% CI, 0.88-0.94]; 271-600 g, OR, 0.90 [95% CI, 0.87-0.93]; 601-1080 g, OR, 0.95 [95% CI, 0.92-0.98]). Doses of more than 1080 g of metformin over 2 years did not have reduced odds of developing AMD. Both the reduction in odds ratio and the dose-dependent response were preserved in a cohort consisting only of patients with diabetes. The authors suggest that metformin may help to prevent AMD and advocate for prospective clinical trials. See more details here.
Metformin may reduce age-related macular degeneration
Feb 3, 2021